Next-Generation Delivery Vehicles for Recombinant Human Bone Morphogenetic Protein-2: A Critical Analysis of Current Trends
Aditya Ramchandra Nemade, Tanmoy Ghosh, Ammunje Damodar Nayak, Vineeth Kumar K., Shruthi N., Shwetha V., Mrinmoy Basak, Basavaraj B.V.Introduction:
The increasing incidence of bone fractures worldwide underscores the need for effective regenerative therapies. However, conventional systemic therapies often compromise patient safety by causing off-target toxicities and reduced effectiveness. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a potent osteoinductive factor; however, its clinical use has traditionally been limited by the side effects associated with its high doses. This review provides a comprehensive comparative analysis of the advantages and disadvantages of both systemic and localized delivery strategies to maximize bone repair while minimizing adverse effects.
Methods:
A literature review using the PubMed, Scopus, and Clinicaltrials.gov databases, encompassing seminal researchers and clinical trials on dosage forms of rhBMP-2 between 2020 and 2024, was conducted. Selection was based on inclusion criteria prioritizing peer-reviewed studies of nextgeneration delivery platforms, while exclusion criteria filtered out studies lacking comparative data on release kinetics or protein stability. This review compares the pharmacological behavior of nextgeneration carriers, including hydrogels, microspheres, and nanosilicates, with conventional collagen sponges in terms of release kinetics, protein stability, and osteogenic efficacy.
Results:
Although rhBMP-2 is an effective natural osteoinductive agent, traditional carriers often exhibit burst release kinetics, leading to localized inflammation and ectopic bone formation. The use of nanotechnology-based advanced formulations and bioengineered scaffolds enables better spatiotemporal regulation, significantly reducing the dose requirements and increasing local retention. Clinical experience with such precision systems has demonstrated their effectiveness in enhancing outcomes in complex orthopedic surgeries, such as spinal fusion and alveolar ridge preservation.
Discussion:
The shift to localized systems that deliver rhBMP-2 therapy topographically would overcome the main shortcomings of the system, namely, systemic leakage and immune activation. Nevertheless, the creation of such sophisticated carriers poses challenges in terms of manufacturing scalability and affordability, which must be addressed for widespread adoption.
Conclusion:
The incorporation of rhBMP-2 is still considered a milestone in regenerative medicine. The future of orthopedics lies in a balanced transition toward targeted delivery methods that incorporate personalized scaffold design and cost-control strategies, enabling the realistic leveraging of osteoinductive potential through the most convenient and least risky treatment options.